R&D update: Dong-A seeks to expand udenafil's uses with new indications
This article was originally published in Scrip
Executive Summary
Udenafil, a phosphodiesterase-5 (PDE-5) inhibitor developed by South Korea's Dong-A Pharmaceutical, is moving forward in a number of new indications on top of its main commercial use for erectile dysfunction (ED).